

**Richard G. Bennett, M.D.**  
**President**

**Executive Offices**  
4940 Eastern Avenue  
Baltimore, MD 21224  
410-550-0781 T  
410-550-7996 F  
rbennett@jhmi.edu



March 10, 2016

Dear Manufacturers,

I am writing on behalf of Johns Hopkins Bayview Medical Center, Inc. (Bayview) to inform manufacturers that Bayview recently underwent an audit by the Health Resources and Services Administration (HRSA) of Bayview's compliance with 340B Drug Pricing Program (340B Program) requirements. Bayview's 340B ID is DSH210029.

As background, Bayview qualified for the 340B Program as a disproportionate share hospital. Bayview is located in Baltimore, Maryland and has participated in the 340B Program since October 1, 2001.

Through the audit process, HRSA found Bayview to be non-compliant with 340B Program requirements and responsible for repayment as a result of the following findings:

Bayview dispensed 340B drugs to ineligible individuals as prohibited by section 340B(a)(5)(B) of the PHSA.

Bayview has identified all affected manufacturers and has contacted each to notify them of these violations and to begin a dialogue on a method for repayment. If manufacturers have not received notification from Bayview and believe repayment may be owed for the findings described in this letter, or if they have any questions or comments regarding the findings described in this letter, please contact:

Shirley Geize, R.Ph.  
Assistant Director, Purchasing and  
Contracting for Pharmacy  
The Johns Hopkins Hospital  
Department of Pharmacy  
600 N. Wolfe Street - Carnegie 180  
Baltimore, MD 21287  
E-mail: [sgeize@jhmi.edu](mailto:sgeize@jhmi.edu)  
Telephone number: 410-955-0382

Sincerely,

/s/

Richard G. Bennett, M.D.